company background image
IMVT logo

Immunovant NasdaqGS:IMVT Stock Report

Last Price

US$32.52

Market Cap

US$4.7b

7D

3.0%

1Y

107.0%

Updated

27 Mar, 2024

Data

Company Financials +

Immunovant, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immunovant
Historical stock prices
Current Share PriceUS$32.52
52 Week HighUS$45.58
52 Week LowUS$14.05
Beta0.72
1 Month Change-14.76%
3 Month Change-23.21%
1 Year Change107.00%
3 Year Change102.74%
5 Year Changen/a
Change since IPO226.83%

Recent News & Updates

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12
Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Recent updates

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12
Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30
Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Shareholder Returns

IMVTUS BiotechsUS Market
7D3.0%0.9%0.4%
1Y107.0%10.3%28.8%

Return vs Industry: IMVT exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: IMVT exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Average Weekly Movement6.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: IMVT's share price has been volatile over the past 3 months.

Volatility Over Time: IMVT's weekly volatility has decreased from 16% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a164Pete Salzmannhttps://immunovant.com

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York.

Immunovant, Inc. Fundamentals Summary

How do Immunovant's earnings and revenue compare to its market cap?
IMVT fundamental statistics
Market capUS$4.72b
Earnings (TTM)-US$243.45m
Revenue (TTM)n/a

0.0x

P/S Ratio

-19.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMVT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$243.45m
Earnings-US$243.45m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.68
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IMVT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.